In its Q1 18 trading update, Hikma put on a brave face and maintained its FY 18 guidance – group level. The injectables business is expected to deliver sales of $750-800m, but the core operating margin is likely to retreat to low-to-mid 30s from the earlier level of the 40s, as the shortage-driven growth moderates and pricing power diminishes. The pressure in the generics business is unlikely to dissipate with additional expenses towards repeat trials for generic Advair Diskus. FY18 rev
12 Jul 2018
FY 18 guidance maintained but no respite on the horizon
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY 18 guidance maintained but no respite on the horizon
Hikma Pharmaceuticals Plc (HIK:LON) | 1,840 754.4 2.3% | Mkt Cap: 4,083m
- Published:
12 Jul 2018 -
Author:
Kamla Singh -
Pages:
3
In its Q1 18 trading update, Hikma put on a brave face and maintained its FY 18 guidance – group level. The injectables business is expected to deliver sales of $750-800m, but the core operating margin is likely to retreat to low-to-mid 30s from the earlier level of the 40s, as the shortage-driven growth moderates and pricing power diminishes. The pressure in the generics business is unlikely to dissipate with additional expenses towards repeat trials for generic Advair Diskus. FY18 rev